Metropolitan Life Insurance Co. NY acquired a new stake in shares of Ignyta, Inc. (NASDAQ:RXDX) during the first quarter, according to its most recent filing with the SEC. The fund acquired 23,356 shares of the biopharmaceutical company’s stock, valued at approximately $201,000. Metropolitan Life Insurance Co. NY owned approximately 0.06% of Ignyta as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of RXDX. Victory Capital Management Inc. raised its stake in shares of Ignyta by 16.2% in the first quarter. Victory Capital Management Inc. now owns 2,804,834 shares of the biopharmaceutical company’s stock valued at $24,122,000 after buying an additional 390,741 shares during the period. Broadfin Capital LLC raised its stake in shares of Ignyta by 16.9% in the first quarter. Broadfin Capital LLC now owns 2,637,346 shares of the biopharmaceutical company’s stock valued at $22,681,000 after buying an additional 380,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Ignyta by 10.4% in the first quarter. Vanguard Group Inc. now owns 1,228,177 shares of the biopharmaceutical company’s stock valued at $10,562,000 after buying an additional 115,212 shares during the period. RA Capital Management LLC bought a new stake in shares of Ignyta during the first quarter valued at about $8,818,000. Finally, Frazier Management LLC raised its stake in shares of Ignyta by 2.5% in the first quarter. Frazier Management LLC now owns 973,693 shares of the biopharmaceutical company’s stock valued at $8,374,000 after buying an additional 23,327 shares during the period. Hedge funds and other institutional investors own 80.82% of the company’s stock.

Shares of Ignyta, Inc. (NASDAQ:RXDX) traded up 16.010% during mid-day trading on Thursday, reaching $11.775. 1,442,035 shares of the company’s stock were exchanged. Ignyta, Inc. has a 52 week low of $4.15 and a 52 week high of $12.00. The stock’s market cap is $662.38 million. The stock has a 50 day moving average price of $9.59 and a 200 day moving average price of $8.67.

Ignyta (NASDAQ:RXDX) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.07. Equities research analysts predict that Ignyta, Inc. will post ($2.57) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/metropolitan-life-insurance-co-ny-invests-201000-in-ignyta-inc-rxdx/1534504.html.

A number of analysts have issued reports on RXDX shares. ValuEngine upgraded shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. BidaskClub lowered shares of Ignyta from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Jefferies Group LLC reiterated a “buy” rating and set a $27.00 price target on shares of Ignyta in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $15.00 price target on shares of Ignyta and gave the stock a “buy” rating in a research note on Monday, July 10th. Finally, Zacks Investment Research upgraded shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $17.33.

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta, Inc. (NASDAQ:RXDX).

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.